<DOC>
	<DOCNO>NCT00544765</DOCNO>
	<brief_summary>Primary objective study patient without sufficient sonographic response ( i.e . iNC ) 2 cycle TAC preoperative treatment operable ( T &gt; /= 2cm , N0-2 , M0 ) primary breast cancer : To determine response rate determine sonography ( iRR = iCR+iPR ) 4 cycle docetaxel , doxorubicin cyclophosphamide ( TAC ) 4 cycle vinorelbine capecitabine ( NX ) ( TAC vs. NX ) Primary objective study patient sufficient sonographic response ( i.e . iRR = iPR iCR ) first 2 cycle TAC preoperative treatment operable ( T &gt; /=2cm , N0-2 , M0 ) primary breast cancer : To determine pCR rate 6 cycle vs. 8 cycle docetaxel , doxorubicin cyclophosphamide ( TAC x 6 vs. TAC x 8 )</brief_summary>
	<brief_title>Docetaxel , Doxorubicin Cyclophosphamide Versus Vinorelbine Capecitabine Patients Not Sufficiently / Sufficiently Responding Preoperative Treatment Locally Advanced Operable Primary Breast Cancer</brief_title>
	<detailed_description>Prospective , randomized phase III trial Study population I : operable ( T &gt; /=2cm , N0-2 , M0 ) primary breast cancer Study population II : locally advance ( T4 a-d , N0-3 , M0 ) primary breast cancer patient All patient receive 2 cycle TAC . Thereafter - Patients sufficiently respond ( iPR , iCR ) randomize either 4 cycle TAC 6 cycle TAC - Patients non-sufficiently respond ( iNC ) randomize either 4 cycle TAC 4 cycle NX : TAC : Docetaxel 75 mg/m² 1 hour i.v . infusion day 1 every 3 week combination Doxorubicin 50 mg/m² i.v . bolus Cyclophosphamide 500 mg/m2 i.v . bolus day 1 every 3 week NX : Vinorelbine 25 mg/m² 10 min i.v . infusion day 1 8 repeat every 3 week Capecitabine 2000 mg/m² orally 2 daily dos day 1-14 repeat every 3 week If patient show progressive disease first 2 cycle TAC randomize treat accord discretion investigator . In patient disease progression preoperative therapy , treatment discontinue patient treat immediate surgery . In case inoperability even termination chemotherapy treatment discretion investigator ( e.g . radiotherapy ) . Dose reduction and/or treatment delay treatment discontinuation plan case severe hematological and/or non-hematological toxicity . After completion chemotherapy assessment response , patient undergo surgery . Surgery perform 1-14 day completion ( i.e . day 21 ) last chemotherapy cycle . If tumor still large breast conservation , modify radical mastectomy recommend . The patient offer autologous heterologous reconstructive surgery . Sentinel node biopsy allow dissected axillary lymph node patient pathological complete response non involve sentinel node . Surgical report collect analyze centrally . The excised breast tissue examine pathologist accord guideline give appendix . Histology report collect analyze centrally . Radiotherapy apply accord guideline . Further postoperative systemic treatment plan except tamoxifen 20 mg p.o . daily 5 year ( start surgery ) patient positive estrogen and/or progesterone receptor unless contraindication use tamoxifen therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Written informed consent must obtain document accord local regulatory requirement prior begin specific protocol procedure . Complete baseline documentation send SKM CRS . Unilateral bilateral primary carcinoma breast , confirm histologically core biopsy . Fineneedle aspiration sufficient . Incisional biopsy allow . In case bilateral cancer investigator decide prospectively side evaluate primary endpoint . Tumor lesion breast palpable size &gt; 2 cm maximum diameter . The leasion measurable twodimensions sonography . In case inflammatory disease extent inflammation use measurable lesion . The following tumor stage eligible : Palpable breast tumor size &gt; 2 cm without involvement skin muscle evidence inflammatory disease ( T23 ) . Clinical N02 . ( Study population I ) Primary tumor clinical involvement skin muscle clinically evidence inflammatory breast cancer ( T4 ad ) clinical N3 include supraclavicular node . ( Study population II ) . In patient multifocal multicentric breast cancer , large lesion measure . Age &gt; 18 year . Karnofsky Performance status index &gt; 80 % . Normal cardiac function must confirm LVEF shorten fraction ( echocardiography MUGA scan respectively ) within 3 month prior registration . The result must normal limit institution . Laboratory requirement ( within 14 day prior registration ) : Hematology : Neutrophils &gt; 2.0 x 109/L Platelets &gt; 100 x 109/L Hemoglobin &gt; 10 g/dL Hepatic function : Total bilirubin &lt; 1 x UNL ASAT ( SGOT ) ALAT ( SGPT ) &lt; 2.5 x UNL Alkaline phosphatase &lt; 5 UNL . Patients ASAT and/or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study . Renal function : Creatinine &lt; 175 µmol/L ( 2 mg/dL ) Tissue block centrally available biological test . Negative pregnancy test ( urine serum ) within 14 day prior registration woman childbearing potential . Complete stag workup within 3 month prior registration . All patient must bilateral mammography , breast ultrasound , breast MRI ( optional ) , chest Xray ( PA lateral ) , abdominal ultrasound and/or CT scan , bone scan . In case positive bone scan , bone Xray mandatory . Other test may perform clinically indicate . Patients must available compliant treatment followup . Patients register trial must treat follow participate center Principal Co Investigator 's site . Early breast cancer tumor size &lt; 2 cm measure palpation . Patients low moderate risk . These patient define none follow risk factor : Age &lt; 36 year , cT &gt; 5cm , ER PR negative , cN+ , Grade III . Evidence distant metastasis . Prior chemotherapy malignancy . Pregnant lactating patient . Patients childbearing potential must implement adequate nonhormonal contraceptive measure study treatment . Preexisting motor sensory neuropathy severity &gt; grade 2 NCI criterion . Other serious illness medical condition : previous malignant disease diseasefree survival le 5 year ( except CIS Cervix nonmelanomatous skin cancer . congestive heart failure unstable angina pectoris , previous history myocardial infarction within 1 year prior study entry , uncontrolled arterial hypertension highrisk uncontrolled arrhythmias . history significant neurologic psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent . active uncontrolled infection . active peptic ulcer , unstable diabetes mellitus . Chronic treatment corticosteroid unless initiate &gt; 6 month prior study entry low dose ( &lt; /= 20 mg methylprednisolone equivalent ) . Concurrent treatment sex hormone . Prior treatment must stop study entry . Definite contraindication use corticosteroid . Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry . Concurrent treatment anticancer therapy . Known hypersensitivity reaction one investigational compound incorporated substance . Male patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>pCR rate</keyword>
</DOC>